Emergent Biosolut Stock Fundamentals
| ER4 Stock | EUR 9.49 0.01 0.11% |
EMERGENT BIOSOLUT fundamentals help investors to digest information that contributes to EMERGENT BIOSOLUT's financial success or failures. It also enables traders to predict the movement of EMERGENT Stock. The fundamental analysis module provides a way to measure EMERGENT BIOSOLUT's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EMERGENT BIOSOLUT stock.
EMERGENT |
EMERGENT BIOSOLUT Company Revenue Analysis
EMERGENT BIOSOLUT's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current EMERGENT BIOSOLUT Revenue | 1.12 B |
Most of EMERGENT BIOSOLUT's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, EMERGENT BIOSOLUT is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, EMERGENT BIOSOLUT reported 1.12 B of revenue. This is much higher than that of the sector and significantly higher than that of the Other industry. The revenue for all Germany stocks is notably lower than that of the firm.
EMERGENT BIOSOLUT Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining EMERGENT BIOSOLUT's current stock value. Our valuation model uses many indicators to compare EMERGENT BIOSOLUT value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across EMERGENT BIOSOLUT competition to find correlations between indicators driving EMERGENT BIOSOLUT's intrinsic value. More Info.EMERGENT BIOSOLUT is rated # 2 in current valuation category among its peers. It is rated # 5 in price to book category among its peers . The ratio of Current Valuation to Price To Book for EMERGENT BIOSOLUT is about 3,145,353,769 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the EMERGENT BIOSOLUT's earnings, one of the primary drivers of an investment's value.EMERGENT Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EMERGENT BIOSOLUT's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of EMERGENT BIOSOLUT could also be used in its relative valuation, which is a method of valuing EMERGENT BIOSOLUT by comparing valuation metrics of similar companies.EMERGENT BIOSOLUT is currently under evaluation in revenue category among its peers.
EMERGENT Fundamentals
| Current Valuation | 1.34 B | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 1.12 B | |||
| EBITDA | (41.1 M) | |||
| Net Income | (223.8 M) | |||
| Total Debt | 448.5 M | |||
| Cash Flow From Operations | (34.1 M) | |||
| Number Of Employees | 18 | |||
| Market Capitalization | 1.91 B | |||
| Total Asset | 3.17 B | |||
| Z Score | 2.4 | |||
| Net Asset | 3.17 B |
About EMERGENT BIOSOLUT Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EMERGENT BIOSOLUT's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EMERGENT BIOSOLUT using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EMERGENT BIOSOLUT based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.